NO317097B1 - N-benzyl-3-indenylacetamidderivater for behandling av neoplasi - Google Patents
N-benzyl-3-indenylacetamidderivater for behandling av neoplasi Download PDFInfo
- Publication number
- NO317097B1 NO317097B1 NO20002972A NO20002972A NO317097B1 NO 317097 B1 NO317097 B1 NO 317097B1 NO 20002972 A NO20002972 A NO 20002972A NO 20002972 A NO20002972 A NO 20002972A NO 317097 B1 NO317097 B1 NO 317097B1
- Authority
- NO
- Norway
- Prior art keywords
- group
- hydrogen
- alkyl
- fluoro
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/989,353 US5948779A (en) | 1997-12-12 | 1997-12-12 | Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes |
| US09/206,245 US6066634A (en) | 1997-12-12 | 1998-12-07 | Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia |
| PCT/GB1998/003712 WO1999031065A1 (en) | 1997-12-12 | 1998-12-11 | N-benzyl-3-indenylacetamides derivatives for treating neoplasia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20002972D0 NO20002972D0 (no) | 2000-06-09 |
| NO20002972L NO20002972L (no) | 2000-08-09 |
| NO317097B1 true NO317097B1 (no) | 2004-08-09 |
Family
ID=26901185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20002972A NO317097B1 (no) | 1997-12-12 | 2000-06-09 | N-benzyl-3-indenylacetamidderivater for behandling av neoplasi |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US6166053A (enExample) |
| EP (1) | EP1044187B1 (enExample) |
| JP (1) | JP4307719B2 (enExample) |
| CN (1) | CN100436418C (enExample) |
| AT (1) | ATE257152T1 (enExample) |
| AU (1) | AU752072B2 (enExample) |
| BR (1) | BR9813540A (enExample) |
| CA (1) | CA2314339C (enExample) |
| CZ (1) | CZ298826B6 (enExample) |
| DE (1) | DE69820908T2 (enExample) |
| ES (1) | ES2212383T3 (enExample) |
| HU (1) | HU227153B1 (enExample) |
| IL (1) | IL136603A0 (enExample) |
| NO (1) | NO317097B1 (enExample) |
| NZ (1) | NZ504958A (enExample) |
| PL (1) | PL196936B1 (enExample) |
| TR (1) | TR200001687T2 (enExample) |
| WO (1) | WO1999031065A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2314339C (en) * | 1997-12-12 | 2009-09-08 | Cell Pathways, Inc. | N-benzyl-3-indenylacetamide derivatives for treating neoplasia |
| IL132366A0 (en) * | 1998-10-15 | 2001-03-19 | Cell Pathways Inc | Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds |
| AU2001255849B8 (en) * | 2000-04-19 | 2006-04-27 | Lilly Icos, Llc. | PDE-V inhibitors for treatment of Parkinson's Disease |
| DE10058663A1 (de) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
| WO2002067936A1 (en) * | 2001-02-21 | 2002-09-06 | Cell Pathways, Inc. | Methods for treatment of inflammatory bowel disease |
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| US20030073740A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of lupus erythematosus |
| US6479493B1 (en) * | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
| US20030073711A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of scleroderma |
| CN100398522C (zh) * | 2003-08-20 | 2008-07-02 | Irm责任有限公司 | 组织蛋白酶s的抑制剂 |
| US6995622B2 (en) * | 2004-01-09 | 2006-02-07 | Robert Bosh Gmbh | Frequency and/or phase compensated microelectromechanical oscillator |
| CA2568906C (en) | 2004-06-02 | 2010-09-21 | Merit Diamond Corporation | Comfort interior for jewelry and jewelry including that interior |
| CN1332930C (zh) * | 2005-08-05 | 2007-08-22 | 中国科学院上海有机化学研究所 | 制备乙氰菊酯前体的方法 |
| CA2635093C (en) * | 2006-01-04 | 2012-06-26 | Southern Research Institute | Derivatives of sulindac, use thereof and preparation thereof |
| WO2009022756A1 (ja) * | 2007-08-13 | 2009-02-19 | Katayama Chemical Industries Co., Ltd. | 虚血性疾患の診断及び治療 |
| EP2365746B1 (en) * | 2008-11-04 | 2014-07-16 | Wellstat Therapeutics Corporation | Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids |
| CN109703393A (zh) | 2009-08-07 | 2019-05-03 | 奥克兰联合服务有限公司 | 感应电力传递装置 |
| US20160168108A1 (en) | 2014-12-16 | 2016-06-16 | Adt Pharmaceuticals, Inc. | Method of treating or preventing ras-mediated diseases |
| US9862698B2 (en) | 2014-12-16 | 2018-01-09 | Adt Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
| CN112020354A (zh) | 2018-04-26 | 2020-12-01 | Adt制药有限责任公司 | 抗癌茚类、茚满类、氮杂茚类、氮杂茚满类、药物组合物和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650720B2 (en) * | 1991-03-08 | 1994-06-30 | Fgn, Inc. | Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof |
| US6063818A (en) * | 1996-06-13 | 2000-05-16 | Cell Pathways Inc. | Substituted benzylidene indenyl formamides, acetamides and propionamides |
| US5948779A (en) * | 1997-12-12 | 1999-09-07 | Cell Pathways, Inc. | Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes |
| CA2314339C (en) * | 1997-12-12 | 2009-09-08 | Cell Pathways, Inc. | N-benzyl-3-indenylacetamide derivatives for treating neoplasia |
-
1998
- 1998-12-11 CA CA002314339A patent/CA2314339C/en not_active Expired - Fee Related
- 1998-12-11 PL PL341151A patent/PL196936B1/pl not_active IP Right Cessation
- 1998-12-11 AT AT98959050T patent/ATE257152T1/de not_active IP Right Cessation
- 1998-12-11 WO PCT/GB1998/003712 patent/WO1999031065A1/en not_active Ceased
- 1998-12-11 JP JP2000538992A patent/JP4307719B2/ja not_active Expired - Fee Related
- 1998-12-11 IL IL13660398A patent/IL136603A0/xx active IP Right Grant
- 1998-12-11 DE DE69820908T patent/DE69820908T2/de not_active Expired - Lifetime
- 1998-12-11 ES ES98959050T patent/ES2212383T3/es not_active Expired - Lifetime
- 1998-12-11 EP EP98959050A patent/EP1044187B1/en not_active Expired - Lifetime
- 1998-12-11 CN CNB988118955A patent/CN100436418C/zh not_active Expired - Fee Related
- 1998-12-11 AU AU14981/99A patent/AU752072B2/en not_active Ceased
- 1998-12-11 NZ NZ504958A patent/NZ504958A/xx unknown
- 1998-12-11 CZ CZ20002157A patent/CZ298826B6/cs not_active IP Right Cessation
- 1998-12-11 TR TR2000/01687T patent/TR200001687T2/xx unknown
- 1998-12-11 BR BR9813540-6A patent/BR9813540A/pt not_active Application Discontinuation
- 1998-12-11 HU HU0100170A patent/HU227153B1/hu not_active IP Right Cessation
-
2000
- 2000-01-24 US US09/490,269 patent/US6166053A/en not_active Expired - Lifetime
- 2000-06-09 NO NO20002972A patent/NO317097B1/no not_active IP Right Cessation
- 2000-12-20 US US09/741,970 patent/US6426349B1/en not_active Expired - Fee Related
-
2002
- 2002-07-26 US US10/206,687 patent/US6610854B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NZ504958A (en) | 2003-03-28 |
| PL341151A1 (en) | 2001-03-26 |
| PL196936B1 (pl) | 2008-02-29 |
| NO20002972L (no) | 2000-08-09 |
| CA2314339A1 (en) | 1999-06-24 |
| US6426349B1 (en) | 2002-07-30 |
| EP1044187A1 (en) | 2000-10-18 |
| HUP0100170A3 (en) | 2001-12-28 |
| TR200001687T2 (tr) | 2000-10-23 |
| DE69820908T2 (de) | 2004-12-23 |
| ATE257152T1 (de) | 2004-01-15 |
| AU1498199A (en) | 1999-07-05 |
| AU752072B2 (en) | 2002-09-05 |
| NO20002972D0 (no) | 2000-06-09 |
| HUP0100170A1 (hu) | 2001-07-30 |
| DE69820908D1 (de) | 2004-02-05 |
| CZ298826B6 (cs) | 2008-02-20 |
| WO1999031065A1 (en) | 1999-06-24 |
| CA2314339C (en) | 2009-09-08 |
| BR9813540A (pt) | 2000-10-10 |
| ES2212383T3 (es) | 2004-07-16 |
| EP1044187B1 (en) | 2004-01-02 |
| IL136603A0 (en) | 2001-06-14 |
| HU227153B1 (en) | 2010-08-30 |
| CZ20002157A3 (cs) | 2000-10-11 |
| JP2002508358A (ja) | 2002-03-19 |
| US20030009033A1 (en) | 2003-01-09 |
| US6166053A (en) | 2000-12-26 |
| JP4307719B2 (ja) | 2009-08-05 |
| US6610854B2 (en) | 2003-08-26 |
| CN100436418C (zh) | 2008-11-26 |
| CN1281436A (zh) | 2001-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO317097B1 (no) | N-benzyl-3-indenylacetamidderivater for behandling av neoplasi | |
| US6066634A (en) | Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia | |
| US6211177B1 (en) | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives | |
| US20200062732A1 (en) | Dna-pk inhibitors | |
| TW201127823A (en) | Indole based receptor CRTH2 antagonists | |
| TW201022216A (en) | Compounds, compositions and methods of using same for modulating uric acid levels | |
| ES2238324T3 (es) | Derivados heterocicloalquilsulfonilpirazol como agentes antiinflamatorios/analgesicos. | |
| RS57306B1 (sr) | Inhibitori dnk-pk | |
| TW200808771A (en) | Novel compounds II | |
| JPH08500847A (ja) | アリーリデン及びヘテロアリーリデンオキシインドール誘導体並びに該誘導体の製造方法 | |
| JP3042882B2 (ja) | 抗炎症剤として有用な２−置換−４，６−ジ−第三ブチル−５−ヒドロキシ−１，３−ピリミジン類 | |
| US6028116A (en) | Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia | |
| US6486158B1 (en) | [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia | |
| US20020028936A1 (en) | 1,3-disubstituted indolin-2-ones for neoplasia | |
| JPH0753730B2 (ja) | イミダゾピラゾール誘導体 | |
| WO2013159698A1 (zh) | 稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用 | |
| CN120309588A (zh) | 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途 | |
| US6455703B2 (en) | 1,3,6,-Trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | |
| HK1030947B (en) | N-benzyl-3-indenylacetamides derivatives for treating neoplasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |